Gabapentin in the treatment of uremic itch: An index case and a pilot evaluation

Journal of Nephrology

Volumn 18, Issue 1, 2005, Pages 86-91

  Manenti, Lucio ^a,b   Vaglio, Augusto ^b   Constantino, Ester ^a   Danisi, Domenico ^a   Oliva, Bruno ^a   Pini, Sergio ^a   Prati, Elisabetta ^a   Testori, Angelo ^a  

^a Hospital of Desenzano del Garda   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Gabapentin; Hemodialysis; Itch; Treatment

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPRURITIC AGENT; CETIRIZINE; GABAPENTIN; 4 AMINOBUTYRIC ACID; AMINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC NEUROPATHY; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; LOW DRUG DOSE; MALE; PILOT STUDY; PREVALENCE; PRURITUS; REMISSION; SCORING SYSTEM; TREATMENT FAILURE; ULTRAVIOLET RADIATION; UREMIA; VISUAL ANALOG SCALE; CASE REPORT; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG ADMINISTRATION; KIDNEY POLYCYSTIC DISEASE; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

AGED; AGED, 80 AND OVER; AMINES; ANTIPRURITICS; CYCLOHEXANECARBOXYLIC ACIDS; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PILOT PROJECTS; POLYCYSTIC KIDNEY DISEASES; PRURITUS; RENAL DIALYSIS; UREMIA;

EID: 16844376036     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Schwartz IF, Iaina A. Uraemic pruritus. Nephrol Dial Transplant 1999; 14: 834-9
2. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC. Itch: scratching more than the surface. Q J Med 2003; 96: 7-26.
3. Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, Risler T, Berger ED, Kuiilman U, Mettang T. Naltrexone does not relieve uremic pruritus: results of a randomised, double blind, placebo-controlled crossover study. J Am Soc Nephrol 2000; 11: 514-9.
4. Zucker I, Yosipovitch G, David M, Gafter U, Boner G. Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 2003; 49: 842-6.
5. Gilchrest BA, Rowe JW, Brown RS, Steinman TI, Arndt KA. Ultraviolet phototherapy of uremic pruritus. Long term results and possible mechanisms of action. Ann Intern Med 1979; 91: 17-21.
6. Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus-new perspectives and insights from recent trials. Nephrol Dial Transplant 2002; 17: 1558-63.
7. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant 2004; 19: 1895-901.
8. Silva SR, Viana PC, Lugon NV, Hoette M, Ruzany F, Lugon JR. Thalidomide for the treatment of uremic pruritus: a cross over randomised trial. Nephron 1994; 67: 270-3.
9. Weisshaar E, Dunker N, Rohl FW, Gollnick H. Antipruritic effects of two different 5 HT3 receptor antagonists and an antihistamine in hemodialysis patients. Exp Dermatol 2004; 13: 298-304.
10. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 2000; 101: 359-71.
11. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes. Drugs 2000; 60: 1029-52
12. Comstock TJ, Sica DA, Bockbrader HN, Underwood BA, Sedman AJ. Gabapentin pharmacokinetics in patients with various degrees of renal function.J Clin Pharmacol 1990; 30: 862.
13. Bassilios N, Launay-Vacher V, Khoury N, Rondeau E, Deray G, Sraer JD. Gabapentin neurotoxicity in a chronic haemodialysis patient. Nephrol Dial Transplant 2001; 16: 2112-3.
14. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001; 38: 104-8.
15. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29: 233-49.
16. Yosipovitch G, Greaves MW, Schmeltz M. Itch Lancet 2003; 361: 690-4.
17. Ikoma A, Rukwied R, Stander S, Steinhoff M, Miyachi Y, Schmeltz M. Neurophysiology of pruritus. Arch Dermatol 2003; 1475-8.
18. Zakrzewska-Pniewska B, Jedras M. Is pruritus in chronic uremic patients related to peripheral somatic and autonomic neuropathy? Neurophysiol Clin 2001; 31: 181-93.
19. Togashi Y, Umeuchi H, Okano K, Ando N, Honda T, Kawamura K, Endoh T, Utsumi J, Kamei J, Tanaka T, Nagase H. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002; 435: 259-64.
20. Fishman SM, Caneris OA, Stojanovic MP, Borsook D. Intravenous lidocaine for treatment-resistant pruritus. Am J Med 1997; 102: 584-5.
21. Bueller HA, Bernhard JD, Dubroff LM. Gabapentin treatment for brachioradial pruritus. J Eur Acad Dermatol Venereol 1999; 13: 227-8.
22. Winhoven SM, Coulson IH, Bottomley WW. Brachio-radial pruritus: response to treatment with gabapentin. Br J Dermatol 2004; 150: 786-7.
23. Scheinfeld N. The role of gabapentin in treating diseases with cutaneous manifestations and pain. Int J Dermatol 2003; 42: 491-5.